Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same author

Presentation, Diagnosis, and Treatment of Cutaneous Crohn Disease.

JAMA dermatology·2026
Same author

Trade-offs between nature and people in Ethiopia's protected areas demonstrate challenges in translating global conservation targets into national realities.

Nature ecology & evolution·2026
Same author

Elephant barrier behaviors in response to conflict mitigation fences.

Conservation biology : the journal of the Society for Conservation Biology·2026
Same author

Cutaneous dual nontuberculous mycobacterial infection in an immunocompetent adolescent male.

JAAD case reports·2026
Same author

Twenty-five years of misinterpreting the biodiversity hotspot approach.

Nature ecology & evolution·2025

Related Experiment Video

Updated: Jun 17, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Modelling imperfect adherence to HIV induction therapy.

Rachelle E Miron1, Robert J Smith

  • 1Department of Mathematics and Faculty of Medicine, The University of Ottawa, 585 King Edward Ave, Ottawa, ON K1N6N5, Canada.

BMC Infectious Diseases
|January 13, 2010
PubMed
Summary

Patients can take drug holidays during induction therapy with careful planning. Mathematical modeling shows that adherence during this intense treatment phase is possible with specific drug regimens, guiding future clinical trials.

More Related Videos

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 17, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

  • Mathematical modeling
  • Pharmacology
  • Clinical trial design

Background:

  • Induction-maintenance therapy involves intense initial treatment followed by a simpler long-term regimen.
  • Patients often experience "pill fatigue" during the induction phase, leading to potential treatment interruptions (drug holidays).
  • Current practices lack scientific guidance for managing drug holidays during induction therapy.

Purpose of the Study:

  • To investigate the impact of imperfect adherence during the induction phase of therapy using mathematical modeling.
  • To determine the maximum allowable duration of drug holidays and the minimum required doses to prevent drug resistance.
  • To assess the number of drug holidays feasible during the induction phase.

Main Methods:

  • Utilized mathematical modeling to simulate patient adherence during induction therapy.
  • Analyzed the relationship between drug holiday duration, subsequent dosing, and the development of resistance.
  • Calculated optimal drug holiday parameters for 15 FDA-approved protease-sparing triple-drug regimens.

Main Results:

  • Mathematical models indicate that patients can take multiple drug holidays during a 180-day induction program.
  • Successful management of drug holidays requires adherence to a strict, albeit straightforward, drug-taking schedule following each interruption.
  • The feasibility and parameters of drug holidays are dependent on the specific drug cocktail used.

Conclusions:

  • Partial adherence during induction therapy is manageable, with outcomes contingent on the prescribed drug cocktail.
  • Theoretical predictions align with pilot study findings on short-cycle treatment interruption strategies.
  • The study's findings can inform the design of future clinical trials investigating optimized adherence strategies.